News Tag: English

Lipidor AB (publ) publishes interim report for Q1 2024

STOCKHOLM, Sweden, 22 May 2024 – Today, Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) publishes its interim report for the period January – March 2024. The report is available on the company's website lipidor.se and in the attached pdf. To read the quarterly report (in Swedish) click here: https://lipidor.se/investors/financial-reports/ Summary of first quarter […]

Bulletin from the Extraordinary General Meeting of Lipidor AB (publ)

The following resolutions were passed at the Extraordinary General Meeting (the “EGM”) of Lipidor AB (publ) (the “Company”) on 21 May 2024 in Stockholm. Rights issue of unitsThe EGM resolved to approve the Board of Directors’ resolution on a new issue of units, consisting of shares and warrants of series TO 2, with pre-emption rights […]

Lipidor AB (publ) publishes annual report for 2023

STOCKHOLM, Sweden, 15th May 2024 – Today, Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) publishes its annual report for the financial year 2023. The report is available on the company's website lipidor.se and in the attached pdf (in Swedish). To read the report in full (in Swedish) click here: https://lipidor.se/investors/financial-reports/ The information was provided […]

NOTICE OF ANNUAL GENERAL MEETING IN LIPIDOR AB (PUBL)

The shareholders of Lipidor AB (publ) reg. no. 556779-7500 (the “Company”) are hereby given notice to attend the Annual General Meeting (the “AGM”) on 5 June 2024 at 09.00 CEST at Fredersen Advokatbyrå, Birger Jarlsgatan 8 in Stockholm. Registration starts at 08.30 CEST. NOTE: This is an unofficial translation of the original Swedish notice. In […]

Lipidor AB announces new date for publication of Annual Report 2023

Lipidor AB (publ) today announces that the Board of Directors has resolved to postpone the publication of the Annual Report for 2023 to 15 May 2024. The previously communicated date for publication was 24 April 2024. The reason for the postponement is to synchronise the Annual Report work with the work on the Company's forthcoming […]

NOTICE OF EXTRAORDINARY GENERAL MEETING IN LIPIDOR AB (PUBL)

The shareholders of Lipidor AB (publ) reg. no. 556779-7500 (the “Company”) are hereby given notice to attend the Extraordinary General Meeting (the “EGM”) on 21 May 2024 at 10.00 CEST at Fredersen Advokatbyrå, Birger Jarlsgatan 8 in Stockholm. Registration starts at 09.30 CEST. NOTE: This is an unofficial translation of the original Swedish notice. In […]

Lipidor resolves on a rights issue of approximately SEK 58.0 million and enters into a co-investment agreement which secures funding for the implementation of the upcoming phase III study

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, WHETHER DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, BELARUS OR ANY OTHER JURISDICTION WHERE SUCH DISTRIBUTION FURTHER REQUIRES PROSPECTUS, REGISTRATION, OR OTHER ACTIONS OTHER THAN THOSE UNDER SWEDISH LAW, ARE PROHIBITED, OR OTHERWISE […]

Lipidor completes planned divestment of shares in Emollivet

STOCKHOLM, Sweden, 26th March 2024 – Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) announces today that the remaining holding of shares in Emollivet AB has been divested according to plan and amounting to 467 KSEK. As previously announced, Lipidor has carried out a phased divestment of its holding in Emollivet AB. As of […]

Lipidor adds capital through sale of shares

STOCKHOLM, Sweden, 6th March 2024 – Today, Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) announces that 100 Emollivet shares, corresponding to approximately SEK 0.7 million, have been divested to Cerbios-Pharma SA. As previously announced, Lipidor is carrying out a step-by-step divestment of its holding in the animal company Emollivet AB. A total of […]

Arkiv